Literature DB >> 11972519

Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease.

Antonino Carbone1, Annunziata Gloghini, Donatella Aldinucci, Valter Gattei, Riccardo Dalla-Favera, Gianluca Gaidano.   

Abstract

Biological and clinical studies have shown that Hodgkin's disease (HD) can be divided into two major categories, termed nodular lymphocyte predominance HD (NLP HD) and classic HD (CHD). Within CHD four subtypes have been distinguished: nodular sclerosis, mixed cellularity, lymphocyte rich and lymphocyte depletion. To refine the histogenesis of the pathological spectrum of HD, 75 CHD and 13 NLP HD were analysed for the expression pattern of MUM1/IRF4 (Multiple Myeloma-1/Interferon Regulatory Factor-4), a lymphocyte-specific member of the IRF family, that is expressed by late centrocytes and post-germinal centre (GC) B cells. MUM1 reacted with Hodgkin's and Reed-Sternberg (HRS) cells of all CHD cases (75/75 cases), with a moderate to strong staining intensity. Conversely, lymphocyte and histiocyte (L &amp; H) cells, the putative tumour cells of NLP HD, were negative for MUM-1 expression (9/13 cases) or displayed a weak reactivity for the antigen in < 10% neoplastic cells (4/13 cases). With respect to HD microenvironment, NLP HD displayed numerous MUM1-positive T lymphocytes located in close proximity to L &amp; H cells whereas, in CHD, MUM1-positive T lymphocytes appeared to be distributed randomly with no specific relationship with HRS cells. Overall, this study shows that MUM1 expression differs in L &amp; H cells versus HRS cells, corroborating the notion that NLP HD and CHD represent different stages of B-cell differentiation. As MUM1-positive T lymphocytes form rosettes around tumour cells of NLP HD, but not of CHD, these data point also to differences in the microenvironment of NLP HD and CHD, and postulate an interactive role of MUM1-positive T lymphocytes with L &amp; H cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972519     DOI: 10.1046/j.1365-2141.2002.03456.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments.

Authors:  Cigdem Atayar; Anke van den Berg; Tjasso Blokzijl; Marcel Boot; Randy D Gascoyne; Lydia Visser; Sibrand Poppema
Journal:  J Clin Pathol       Date:  2006-12-08       Impact factor: 3.411

2.  A definitive diagnosis of primary Hodgkin lymphoma on endoscopic biopsy material utilizing in-depth immunohistochemical analysis.

Authors:  Garnet Horne; Shaun A C Medlicott; Adnan Mansoor; Johan Lategan; Raymond Lai; P Beck
Journal:  Can J Gastroenterol       Date:  2007-03       Impact factor: 3.522

3.  Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation.

Authors:  Clarissa D Osswald; Linka Xie; Hanfeng Guan; Franziska Herrmann; Sarah M Pick; Marion J Vogel; Franziska Gehringer; Fong Chun Chan; Christian Steidl; Thomas Wirth; Alexey Ushmorov
Journal:  Blood       Date:  2018-02-13       Impact factor: 22.113

Review 4.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

5.  An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.

Authors:  A Lollies; S Hartmann; M Schneider; T Bracht; A L Weiß; J Arnolds; L Klein-Hitpass; B Sitek; M-L Hansmann; R Küppers; M A Weniger
Journal:  Leukemia       Date:  2017-06-29       Impact factor: 11.528

6.  Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival.

Authors:  Yasodha Natkunam; Eric D Hsi; Patricia Aoun; Shuchun Zhao; Paul Elson; Brad Pohlman; Hina Naushad; Martin Bast; Ronald Levy; Izidore S Lossos
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

7.  Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.

Authors:  Gabriela Gualco; Eduardo M Queiroga; Lawrence M Weiss; Claudete E N Klumb; William J Harrington; Carlos E Bacchi
Journal:  Hum Pathol       Date:  2009-01-13       Impact factor: 3.466

8.  Diagnostic impact of molecular lineage analysis on paraffin-embedded tissue in hematolymphoid neoplasia reclassified by current WHO criteria.

Authors:  Leonard Hwan Cheong Tan; Lily-Lily Chiu; Evelyn Siew Chuan Koay
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.

Authors:  Kui Nie; Mario Gomez; Pablo Landgraf; Jose-Francisco Garcia; Yifang Liu; Leonard H C Tan; Amy Chadburn; Thomas Tuschl; Daniel M Knowles; Wayne Tam
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

10.  Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility.

Authors:  Junke Wang; Alyssa I Clay-Gilmour; Ezgi Karaesmen; Abbas Rizvi; Qianqian Zhu; Li Yan; Leah Preus; Song Liu; Yiwen Wang; Elizabeth Griffiths; Daniel O Stram; Loreall Pooler; Xin Sheng; Christopher Haiman; David Van Den Berg; Amy Webb; Guy Brock; Stephen Spellman; Marcelo Pasquini; Philip McCarthy; James Allan; Friedrich Stölzel; Kenan Onel; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Front Genet       Date:  2021-06-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.